Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2267]

FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer

FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a...

ASH 2024: Study finds genetic changes, elevated leukaemia risk in ground zero first responders

ASH 2024: Study finds genetic changes, elevated leukaemia risk in ground zero first responders

Regional, racial, and economic disparities in cancer risk from air pollution exposure persist, but improving, new research suggests

Regional, racial, and economic disparities in cancer risk from air pollution exposure persist, but improving, new...

European alliance against cancer in children and adolescents

European alliance against cancer in children and adolescents

Collaborators host inaugural convening to promote advancement of global cancer detection efforts

Collaborators host inaugural convening to promote advancement of global cancer detection efforts

Amivantamab in combination with lazertinib for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

Amivantamab in combination with lazertinib for the first-line treatment of patients with EGFR-mutated advanced non...

$FDA approves revumenib for relapsed or refractory acute leukaemia with a KMT2A translocation$

FDA approves revumenib for relapsed or refractory acute leukaemia with a KMT2A translocation

Study reveals significant global disparities in cancer care across different countries

Study reveals significant global disparities in cancer care across different countries

FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma

FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma

More from ecancer